SCHEMBL6807340

SCHEMBL6807340

O=c1cc(-c2ncccn2)oc2cccc(OCc3ccc(F)cc3)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.57
ACHE P22303 1/20 0.57
AR P10275 4/20 0.51
MAOB P27338 2/20 0.46
MAOA P21397 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
BRD4 O60885 1/20 0.45
HPGD P15428 2/20 0.44
SGMS2 Q8NHU3 1/20 0.43
ABCG2 Q9UNQ0 3/20 0.42
ABCB1 P08183 2/20 0.42
PLG P00747 2/20 0.42
ELANE P08246 2/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TP53 P04637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2486552 0.86 BCHE (0.53) BCHEACHEARMAOBMAOA
SCHEMBL752572 0.84 BCHE (0.50) BCHEACHEARMAOBMAOA
SCHEMBL756733 0.83 BCHE (0.49) BCHEACHEARMAOBMAOA
SCHEMBL757274 0.79 BCHE (0.50) BCHEACHEARMAOBMAOA
SCHEMBL6896786 0.79 BCHE (0.52) BCHEACHEARMAOBMAOA
SCHEMBL2486966 0.77 KMT2A (0.44) BCHEACHEMAOBMAOAMEN1
SCHEMBL17523234 0.72 BCHE (0.82) BCHEACHEARMAOBMEN1
SCHEMBL15619737 0.71 BCHE (0.66) BCHEACHEARMAOBMEN1
SCHEMBL753327 0.70 AR (0.47) BCHEACHEARMAOBMAOA
SCHEMBL6896780 0.70 BRD4 (0.43) BCHEACHEARMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266958-B1 Antiviral agent SHIONOGI & CO (JP) 2017-03-15 EP disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
EP-3042894-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2016-07-13 EP disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT BCHE 2050/4885ACHE 2914/4885AR 951/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI BCHE 1478/4885ACHE 1249/4885AR 469/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI BCHE 1478/4885ACHE 1249/4885AR 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.